Combination of PI3K inhibitor BAY 1082439 with radium-223 is a promising treatment of cancer with bone metastases

被引：0
|
作者：
Suominen, Mari I. [1 ]
Fagerlund, Katja [1 ]
Stasik, Enrico [2 ]
Haegebarth, Andrea [2 ]
Scholz, Arne [2 ]
Rissanen, Jukka P. [1 ]
Kornacker, Martin [2 ]
Mumberg, Dominik [2 ]
Halleen, Jussi M. [1 ]
Ziegelbauer, Karl [2 ]
Liu, Ningshu [2 ]
机构：
[1] Pharmatest Serv Ltd, Turku, Finland
[2] Bayer Pharma AG, Berlin, Germany
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4022
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PI3K inhibitor BAY 1082439 and radium-223 dichloride decrease tumor burden and tumor-induced bone formation in an established bone metastatic prostate cancer model in mice
    Suominen, Mari I.
    Morko, Jukka
    Fagerlund, Katja M.
    Alhoniemi, Esa
    Mumberg, Dominik
    Ziegelbauer, Karl
    Halleen, Jussi M.
    Scholz, Arne
    Liu, Ningshu
    CANCER RESEARCH, 2016, 76
  • [2] Activity of BAY1082439, a balanced PI3Kα/β inhibitor, in gastric cancer
    Hung, Huynh T.
    Ong, Richard
    Haike, Katja
    Petrova, Elissaveta
    Chong, Mei Ling
    Loh, Marie
    Bhattacharya, Bhaskar
    Soong, Richie
    Liu, Ningshu
    CANCER RESEARCH, 2015, 75
  • [3] Radium-223 Therapy of Bone Metastases in Prostate Cancer
    Nilsson, Sten
    SEMINARS IN NUCLEAR MEDICINE, 2016, 46 (06) : 544 - 556
  • [4] Mechanistic Modeling of Radium-223 Treatment of Bone Metastases
    Moreira, Hugo M. R.
    Guerra Liberal, Francisco D. C.
    O'Sullivan, Joe M.
    McMahon, Stephen J.
    Prise, Kevin M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (05): : 1221 - 1230
  • [5] Radium-223 as an Approved Modality for Treatment of Bone Metastases
    Brito, Ana Emilia
    Etchebehere, Elba
    SEMINARS IN NUCLEAR MEDICINE, 2020, 50 (02) : 177 - 192
  • [6] Investigation of the safety of Radium-223 chloride in combination with external beam radiotherapy for bone metastases of prostate cancer
    Makino, Soichi
    Miyazawa, Kazunari
    Katsuoka, Yoji
    Ooe, Takeru
    Aikawa, Ken
    Segawa, Akira
    Kobayashi, Hiroshi
    JOURNAL OF RADIATION RESEARCH, 2025,
  • [7] Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why
    Gallicchio, Rosj
    Mastrangelo, Pietro A.
    Nardelli, Anna
    Mainenti, Pier Paolo
    Colasurdo, Antonio P.
    Landriscina, Matteo
    Guglielmi, Giuseppe
    Storto, Giovanni
    TUMORI JOURNAL, 2019, 105 (05): : 367 - 377
  • [8] Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases
    Wakita, Naoto
    Hara, Takuto
    Suzuki, Kotaro
    Terakawa, Tomoaki
    Teishima, Jun
    Nakano, Yuzo
    Miyake, Hideaki
    ANTICANCER RESEARCH, 2024, 44 (06) : 2627 - 2635
  • [9] Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439
    Zou, Yongkang
    Qi, Zhi
    Guo, Weilong
    Zhang, Liuzhen
    Ruscetti, Marcus
    Shenoy, Tanu
    Liu, Ningshu
    Wu, Hong
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (10) : 2091 - 2099
  • [10] Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases
    Vogelzang, Nicholas J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 809 - 819
12345